Détail de la notice
Titre du Document
Effects of magnesium on the renin-angiotensin-aldosterone system in human subjects
Auteur(s)
ICHIHARA A. ; SUZUKI H. ; SARUTA T.
Résumé
Recent prospective study of intravenous magnesium sulphate administration into patients with acute myocardial infarction revealed the improvement of survival rate of these patients. This study was designed to determine the effect of intravenous administration of magnesium on the renin-angiotensin-aldosterone (RAA) system. MgSO4 (0.72% in 3.24% glucose solution) at 5 mEq/hr was infused intravenously into six healthy normotensive men for six hours. MgSO4 infusion increased plasma renin activity (PRA) at 60 minutes (4.1 ± 1.4 ng/ml/hr vs 2.7 ± 0.8 ng/ml/hr, p < 0.05) and decreased plasma aldosterone concentration (PAC) at 180 minutes (40 ± 8 pg/ml vs 60 ± 12 pg/ml, p < 0.05). The maximum level of serum magnesium reached 2.32 ± 0.09 mEq/L, from the control value of 1.58 ± 0.07 mEq/L, at 3 hours. Analysis of both serum levels and urinary excretion of electrolytes revealed significant increases in urinary excretion of calcium and magnesium, whereas no significant changes in other electrolytes in serum or urinary excretion were found. To clarify the mechanism by which magnesium increased PRA and suppressed PAC, either prostaglandin synthesis inhibitor, indomethacin (75 mg/day), or a calcium channel blocker, diltiazem (90 mg/day), was administered. Indomethacin completely blocked the increase in PRA but did not induce any changes in PAC. Diltiazem inhibited the decrease in PAC but did not induce any changes in PRA. These data indicate that magnesium stimulates renin
Editeur
Elsevier
Identifiant
PMID : 8228558 ISSN : 0022-2143 CODEN : JLCMAK
Source
The Journal of laboratory and clinical medicine A. 1993, vol. 122, n° 4, pp. 432-440 [bibl. : 38 ref.]
Langue
Anglais
Pour les membres de la communauté du CNRS, ce document est autorisé à la reproduction à titre gratuit.
Pour les membres des communautés hors CNRS, la reproduction de ce document à titre onéreux sera fournie sous réserve d’autorisation du Centre Français d’exploitation du droit de Copie.

Pour bénéficier de nos services (strictement destinés aux membres de la communauté CNRS (Centre National de la Recherche Scientifique), de l'ESR français (Enseignement Supérieur et Recherche), et du secteur public français & étranger) :